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Abstract. To date, information on the ontogeny of renal transporters is limited. Here, we
propose to estimate the in vivo functional ontogeny of transporters using a combined
population pharmacokinetic (popPK) and physiology-based pharmacokinetic (PBPK)
modeling approach called popPBPK. Clavulanic acid and amoxicillin were used as probes
for glomerular filtration, combined glomerular filtration, and active secretion through
OAT1,3, respectively. The predictive value of the estimated OAT1,3 ontogeny function was
assessed by PBPK predictions of renal clearance (CLR) of other OAT1,3 substrates: cefazolin
and piperacillin. Individual CLR post-hoc values, obtained from a published popPK model on
the concomitant use of clavulanic acid and amoxicillin in critically ill children between 1
month and 15 years, were used as dependent variables in the popPBPK analysis. CLR was re-
parameterized according to PBPK principles, resulting in the estimation of OAT1,3-mediated
intrinsic clearance (CLint,OAT1,3,invivo) and its ontogeny. CLint,OAT1,3,invivo ontogeny was
described by a sigmoidal function, reaching half of adult level around 7 months of age,
comparable to findings based on renal transporter-specific protein expression data. PBPK-
based CLR predictions including this ontogeny function were reasonably accurate for
piperacillin in a similar age range (2.5 months–15 years) as well as for cefazolin in neonates as
compared to published data (%RMSPE of 21.2 and 22.8%, respectively and %PE within
±50%). Using this novel approach, we estimated an in vivo functional ontogeny profile for
CLint,OAT1,3,invivo that yields accurate CLR predictions for different OAT1,3 substrates across
different ages. This approach deserves further study on functional ontogeny of other
transporters.
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INTRODUCTION
Pediatric renal clearance (CLR) is driven by physiology
related changes to kidney size, number of glomeruli and
nephron filtration capacity, renal blood flow, expression of
drug binding plasma proteins and expression of transporters.
Throughout the pediatric age-range, the maturation of
glomerular filtration rate (GFR) has been extensively studied
by various groups (1–7), however, less is known about the
functional in vivo development of other processes contribut-
ing to CLR (8) such as active tubular secretion (ATS), which
is mediated through transporters in the kidneys.
In vivo transporter activity cannot be directly quantified
but has to be derived from other measures. Recently, the
ontogeny of individual renal transporters has been quantified
by measuring transporter-specific protein expressions in
postmortem kidney samples from children of different ages
(9). However, there is limited information about how protein
expression relates to in vivo transporter activity and whether
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this relationship remains constant with age. Alternatively,
ontogeny of ATS has been quantified in vivo as net secretion
of drugs with non-selective affinity for transporters. Net
secretion aggregates the activity of all active secretion
transporters involved in renal excretion and of reabsorption
(3, 10). Since ontogeny patterns may differ between trans-
porters, their relative contributions to CLR will also differ
throughout the pediatric age-range, as drugs may have a
broad spectrum in transporter affinity and can be transported
by one or more transporters at once. Therefore, it would be
of relevance to separately quantify the ontogeny of each renal
transporter in vivo. Here we propose a new method to derive
functional transporter ontogeny profiles in vivo.
Empirically, clinical pharmacokinetic (PK) data (i.e.,
concentration-time data) are analyzed using population PK
(popPK) models. When analyzing pediatric PK data, the
inter-individual variability in different parameters is driven by
differences in underlying developing physiological processes.
These differences are usually captured by a function that
describes the relation between the individual deviations in
parameter values from typical parameter values and a
relatively small set of demographic variables that vary with
age, i.e., covariate relationship. In pediatric physiology-based
PK (PBPK) modeling, quantitative knowledge on developing
physiology is included a priori in functions that describe
changes in system-specific parameters. Subsequently, these
models describe the interaction between drugs with certain
physicochemical properties and this system. The parameters
in a PBPK model can be derived from various data sources
(e.g. in vitro experiments, clinical studies, etc.). Recently,
combined popPK and PBPK approaches (which were re-
ferred to as popPBPK approaches, to not be confused with
virtual PBPK populations) have been proposed to derive
physiological measures for PBPK models that cannot be
obtained through direct measures, by leveraging
concentration-time data (11, 12). When selecting drugs that
are predominantly eliminated by one main pathway, infer-
ences can be made regarding system-specific parameters that
are particular for that pathway.
In this study, the ontogeny of in vivo renal organic anion
transporters 1 and 3 (OAT1,3) activity was characterized with
this popPBPK approach. To this end, PK data obtained in
critically ill children of different ages after the concomitant
administration of clavulanic acid and amoxicillin was used.
Each drug was assumed a probe for their specific elimination
pathway, i.e., clavulanic acid for glomerular filtration (GF)
and amoxicillin for a combination of GF and ATS through
OAT1,3 (13, 14). With this methodology the ontogeny
function of OAT1,3 could be estimated. Its predictive value
was assessed by including the ontogeny function in a pediatric
PBPK model to predict CLR of two other OAT1,3 substrates
including cefazolin and piperacillin.
METHODS
Software
For the present analysis we used NONMEM v7.3
integrated with Pirana v2.9.9 for developing the model and
R v3.5 integrated with RStudio for graphics and evaluation.
Quantifying the Ontogeny Function of OAT1,3 In Vivo
Clinical studies showed that the majority of an amoxicil-
lin and clavulanic acid dose is recovered unchanged in urine
(15–18) and in vitro evidence suggests that active secretion of
amoxicillin is mainly mediated through OAT3 and to a lesser
extent by OAT1 (13, 19). Different minor elimination routes
may be involved, yet here we assume the clinical data to
reflect the major elimination routes only. This implies the
assumption that clavulanic acid clearance through other
elimination routes than GF mature at the same rate as GF.
For amoxicillin the extent of clearance through elimination
routes other than active tubular secretion is assumed to be the
same as for clavulanic acid and the difference in clearance
between these two drugs is fully attributed to active tubular
secretion through OAT1/3. Finally, even though the OAT1/3
transporter works in tandem with MRP4 efflux transporters,
the contribution of MRP4 transporters to the CLR of
amoxicillin and for piperacillin and cefazolin, mentioned later
in the “methods” section, was excluded in the current
example as the expression of this transporter was found to
remain constant with age (9).
Individual post-hoc CLR values for clavulanic acid and
amoxicillin in pediatric patients were obtained from a
population PK model of De Cock et al. (20). In short, a
simultaneous popPK analysis was performed for both drugs
based on data obtained after the administration of a fixed
dose ratio of 1:10 (clavulanic acid:amoxicillin) in 50 intensive
care pediatric patients with ages between 1 month and 15
years (median age of 2.6 years) (20). The PK of clavulanic
acid and amoxicillin were described by a two- and a three-
compartment model, respectively, with inter-individual vari-
ability (IIV) on renal clearance (CLR) and central volume of
distribution. The covariate analysis identified current weight
as a statistically significant predictor for the IIV on both
central volume of distribution and CLR, whereas vasopressor
treatment and cystatin C were found to be statistically
significant predictors only for the IIV on CLR (20).
In a sequential step, CLR was re-parameterized accord-
ing to PBPK principles to reflect clearance through glomer-
ular filtration (CLGF) and through active tubular secretion
(CLATS) (Eqs. 1 and 2) (21). The PBPK-based model for CLR
assumes a serial arrangement for GF and ATS, in which CLR
of clavulanic acid was described by CLGF only (CLATS = 0),
while CLR of amoxicillin was described by a combination of
CLGF and CLATS.
CLR ¼ CLGF þ CLATS ¼ GFR f uð Þ þ









CLsec;OAT3 ¼ CLint;OAT3;invivo  ontOAT3  PTCPGK KW ð2Þ
In equation 1, GFR stands for glomerular filtration rate,
fu for drug fraction unbound, QR for renal blood flow,
CLsec,OAT1,3 for secretion clearance through OAT1,3, and
BP for blood to plasma ratio. Equation 2 shows how
CLsec,OAT1,3 is obtained by multiplying CLint,OAT1,3,in vivo that
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stands for OAT1,3-mediated in vivo intrinsic clearance in
adults, with ontOAT1,3 that stands for the ontogeny function
for OAT1,3, PTCPGK that stands for proximal tubule cells
per gram kidney, and KW that stands for kidney weight in
grams.
The adult PBPK-based model for CLR through a
combination of GF and ATS (Eqs. 1 and 2) was extrapolated
to the pediatric population. For this, published functions that
describe the age-related changes of the system-specific
parameters (i.e., GFR (2), renal blood flow (22), and kidney
weight (22)) and of the drug-specific parameters impacted by
changes in system-specific parameters (i.e., serum albumin
concentrations (4) that influence the fraction unbound (23),
and hematocrit levels that influence BP (22)) were inputted,
as shown in Table S1. Values for fu (24) and BPamox .(25) as
reported in adults were used (fu clav.acid = 0.75; fu amox = 0.82;
BPamox.= 0.55). CLint,OAT1,3,in vivo reflects both the expression
and activity of the OAT1,3 transporter in adults. Assuming
PTCPGK to remain constant at adult values, this only leaves
CLint,OAT1,3,in vivo and its ontogeny function (ontOAT1,3) to be
estimated. This was done using the individual CLR values
from the population model as dependent variables and
deriving the system-specific PBPK parameters based on the
individual patient characteristics for each patient.
Pediatric typical CLGF values were obtained using a
published GFR maturation function developed for children
with a normal renal function (2). However, when compared
to normal CLGF values, CLR of both drugs as estimated with
the population PK models, were found to be increased in the
critically ill children included in the dataset of the current
analysis (20). Hence, the PBPK-based re-parameterization of
CLGF included a typical GF correction factor (θcorr) with IIV
(ƞGFR) to account for this difference (equations 3).
CLR;clavulanic acid;i ¼ GFR f uclav: acid  θcorr:  eηGFR ð3Þ
As both amoxicillin and clavulanic acid were adminis-
tered simultaneously to each child, from the data on
clavulanic acid the GF correction factor and IIV on GFR for
each pediatric patient was estimated. According to Eqs. 4 and
5, the difference between the individual values for CLR of
amoxicillin and CLR of clavulanic acid were used to estimate
CLATS, which was the basis for the estimation of the IIV on
the in vivo CLsec,OAT1,3 value and subsequently the OAT1,3
ontogeny function (ontOAT1,3).
CLR;amoxicilin;i ¼ GFR f uamox: θcorr:  eηGFR
þ QR−GFRð Þ  f uamox:  CLsec;OAT1;3;i




CLsec;OAT1;3;i ¼ θCLint;OAT1;3;invivo  eηCLint;OAT3;invivo
 ontOAT1;3  PTCPGK KW ð5Þ
To quantify the ontogeny profile of CLint,OAT1,3,in vivo,
different covariates (i.e. postnatal age, postmenstrual age,
weight) were explored using sigmoid relationships (Eq. 6)
or a simplification of this equation (i.e., an exponential
equation). In Eq. 6, hill is the hill coefficient, which
quantifies the steepness of the ontogeny slope and TM50






The statistical significance of including the ontOAT1,3
function in the equation for CLsec,OAT1,3,i to obtain CLR of
amoxicillin was assessed according to the likelihood ratio test
on the difference in objective function value. Under the
assumption of a χ2 distribution, the objective function value
of a model with one more degree of freedom had to be 3.84
points lower, with a corresponding p < 0.05 to indicate
statistical significance (26). For graphical goodness-of-fit, a
plot was made to check for prediction bias of the individual
CLR values obtained either with the PBPK model or the
individual post hoc values from the population PK model that
served as the dependent variable in these fits. In addition,
ETA (ƞGFR, ƞCLint,OAT1,3,invivo) vs. covariate plots (age,
weight) are made to check for structural accuracy in PK
parameters.
Predictive Properties of the OAT1,3 Ontogeny Function for
New Substrates
To assess the predictive performance of the obtained
OAT1,3 maturation function, the PBPK model that includes
the estimated ontogeny function for OAT1,3 (Eqs. 1 and 2)
was used for pediatric PBPK CLR predictions of piperacillin
and cefazolin, two other substrates of the OAT1,3 transporter.
PBPK predictions of CLR were compared to published typical
pediatric CLR predictions by population PK models of the
same drugs. Population models are considered the gold
standard for deriving CLR values from observed
concentration-time data and since neither the PBPK model
nor the typical predictions by a population PK model take
random inter-individual deviations in CLR into account, they
can be directly compared.
To obtain the pediatric PBPK predictions for CLR, we
collected literature values for fu, adult of 0.8 (27) and 0.31
(25) for piperacillin and cefazolin, respectively, and for BP
adult of 0.55 for both drugs. CLint,OAT1,3,in vivo in Eq. 2 had to
be derived for both drugs. This was done based on
published in vitro activity data as measured in assays with
OAT1,3 transfected cells (1.95 μl/min/mg protein (27) and
7.1 μl/min/mg protein (25) for piperacillin and cefazolin
respectively). These values were further optimized based on
the in vivo adult values for CLint,OAT1,3 using a retrospective
IVIVE approach. More details on the retrospective IVIVE
are provided in the supplemental materials.
The drug-specific CLint,OAT1,3, in vivo values obtained in
the retrospective IVIVE step were used in Eqs. 1 and 2 of the
renal PBPK model to obtain pediatric CLR predictions for
cefazolin and piperacillin. Pediatric PBPK CLR predictions
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for piperacillin and cefazolin were made for typical individ-
uals with the same demographic characteristics as the
individual patients reported in the original publications
describing the pediatric population PK models of these drugs
(20, 28). This means that, for piperacillin, PBPK CLR values
were estimated for 47 pediatric patients with ages between 2.5
months and 15 years (median age of 2.83 years). For
cefazolin, the PBPK CLR values were estimated for 26 near-
term neonates with gestational age higher than 35 weeks and
postnatal age (PNA) between 1 and 30 days (median of 8
days). For this, the OAT3 ontogeny function obtained above
for children of 1 month and older based on data from
clavulanic acid and amoxicillin was extrapolated to the
neonatal population.
Pediatric PBPK CLR predictions were visually and
quantitatively compared to typical estimates obtained with
published population PK models for these two OAT1,3
substrates. Precision was quantified as percentage root
mean square prediction error (%RMSPE) (Eq. 7) and bias
















In both equations, CLR,PBPK are the CLR predictions
obtained with the renal PBPK model in pediatrics and
CLR,reference represents the CLR values for typical CLR
predictions obtained with the published population PK
models (28, 29). %RMSPE and %PE were calculated
separately for piperacillin and cefazolin and reported overall
as well as per age group. CLR,PBPK was considered to be
accurately predicted if %RMSPE and %PE was within
±30%, reasonably accurately predicted between −30–−50%
and 30–50% and inaccurate when %RMSPE and %PE were
outside ±50%. Note that %RMSPE can only take positive
values.
RESULTS
Quantifying the Ontogeny Function of OAT1,3
With the popPBPK approach, CLGF was separated from
CLATS such that CLint,OAT1,3,in vivo and its ontogeny profile
could be estimated in children as young as 1 month up to 15
years of age. Figure 1 shows the ontogeny profile of OAT1,3
as best described by a sigmoidal relationship based on PNA.
CLint, OAT1,3, in vivo was estimated to be 15.8 ml/h/g kidney
(RSE% of 5%) at 15 years with an IIV of 78.5%. This high
IIV suggests large differences between individual values
obtained for CLint, OAT1,3, in vivo. CLint, OAT1,3, in vivo was
found to reach half of the adult capacity at a PNA of 27.3
weeks (RSE of 28%), which is around 7 months. The rapid
ontogeny of OAT1,3 was captured by a hill exponent of 1.17
(%RSE of 36%). The estimated transporter ontogeny
fractions range from 0.1 at 1 month and 1 at 15 years. The
GF correction factor used to account for the increased CLR in
critically ill children was estimated at 1.83 (RSE of 4%) with
an IIV of 24.4%.
The goodness-of-fit plots did not show any bias for CLR
predictions obtained with CLR re-parameterized according
to PBPK principles. Neither Fig. S1, which depicts
popPBPK CLR predictions vs. the popPK CLR predictions,
nor Fig. S2, which depicts the ƞGFR and ƞCLint,OAT1,3,in vivo
vs. covariates (i.e., weight and age) show any bias. This
suggests that the PBPK-based re-parameterization as CLGF
(Eq. 3) can predict individual clavulanic acid CLR values
accurately and that the reparameterization for CLGF
together with CLATS (Eq. 4) can accurately predict the
CLR of amoxicillin as excreted by GF and ATS through
OAT1,3.
Figure 2 shows the total CLR for amoxicillin and the
contribution of CLGF and CLATS to CLR for each individual.
Total CLR increases almost 7-fold between neonates younger
than 1 year and children of 10 years and older (median of 1.64
L/h and 12 L/h, respectively). The median contribution of
ATS to amoxicillin CLR for the studied pediatric population
was 22% (range: 4–40%). Even if variability in ATS
contribution was high within groups of individuals with
similar ages, the ATS contribution increased with age, on
average, from 14% in children younger than 1 year to 18% in
children of 1–2 years, 21% for children of 2–5 years, 24% for
children 5–10 years, reaching 29% for children older than 10
years.
Fig. 1. Ontogeny function for OAT1,3-mediated intrinsic clearance
normalized by kidney weight (CLsec,OAT1,3– blue line) described by a
sigmoidal function based on age and displayed throughout the studied
pediatric age-range (1 month to 15 years), on a double-log scale. The
orange dots represent the individual secretion clearance estimates
normalized by kidney weight. See Eq. [5] for more details
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Predictive Properties of the OAT1,3 Ontogeny Function
Figure 3 shows the pediatric CLR predictions for
piperacillin and cefazolin obtained with the PBPK-based
model and the identified OAT1,3 ontogeny function based
on clavulanic acid and amoxicillin overlaid with the typical
clearance estimates obtained with the published population
PK models. The %RMSPE calculated between PBPK CLR
and typical CLR predictions for piperacillin (Fig. 3a) over the
entire age-range (2.5 months to 15 years) was 21.8% with a
%PE interval between −33.2% and 25.4%. When stratified
per age groups (i.e., younger than 1 year, 1–2 years, 2–5 years,
5–10 years and older than 10 years) %RMSPE is generally
higher for children under 5 years (23.3, 22.2, and 27.4% vs.
14.9, 18.8%). For neonates (Fig. 3b), the %RMSPE calcu-
lated between PBPK CLR and typical CLR predictions for
cefazolin was 22.2% with %PE interval between −34.4 and
46%.
For both pediatric populations the PBPK-based CLR
predictions can be considered reasonably accurate with
%RMPE < 30% and %PE within ±50%. For piperacillin,
the PBPK-based CLR predictions tend towards overpredic-
tion (Fig. 3a), with all %PE values below 0%, although
percentage deviations were acceptable [%PE between −13.3
and −28.8%] for children older than 1 year. For cefazolin in
neonates, predictions are reasonably accurate (Fig. 3b), with
PBPK-based CLR pred i c t ions tend ing towards
underprediction [%PE between 18.1 and 46%] for children
older than 10 days.
DISCUSSION
With a combined population PK with PBPK approach,
referred to as popPBPK, we estimated the functional in vivo
ontogeny profile for OAT1,3, a parameter that cannot be
obtained through direct measurements, down to the age of 1
month. Under the assumption that clavulanic acid is entirely
eliminated through GF and amoxicillin through GF and ATS
through OAT1,3, we used clinical PK data of children that
received both drugs at the time to define a maturation
function for ATS through OAT1,3. Using a population PK
approach, we derived the individual CLR values for both
drugs that served as dependent variable for the popPBPK
approach. CLR was re-parameterized according to PBPK
principles to take advantage of existing information about
drug- and system-specific properties while estimating the
ontogeny of OAT1,3 in vivo and the variability on GFR and
on OAT1,3-mediated intrinsic clearance in vivo (CLint,OAT1,3,
in vivo).
Our group recently developed a PBPK simulation
framework for investigating the impact of ontogeny of renal
secretion transporters on CLR by predicting pediatric CLR for
hypothetical drugs with an array of drug properties (30). By
looking at the difference between PBPK CLR predictions
with or without inclusion of the ontogeny function, probe
drugs for quantifying the ontogeny of transporters were
identified. According to the findings with this framework,
amoxicillin, which has an estimated CLint,OAT1,3, in vivo of 4.4
μl/min/mg protein and a fu of 0.82 (31), has the potential of
serving as a probe to quantify OAT1,3 ontogeny. Further-
more, the clinical data available for probe drugs for GF and a
combination of GF and ATS (clavulanic acid and amoxicillin,
respectively) administrated to the same individuals was
paramount to separate between these two processes.
OAT1,3 ontogeny for the OAT1,3-mediated intrinsic
clearance is steep in the first year of life, attaining half of
the adult value around 7 months of age. This estimated
ontogeny function was included in the pediatric PBPK-based
model for CLR through GF and ATS. Even though the
functional in vivo OAT1,3 ontogeny profile was derived from
clinical data obtained in critically ill patients without renal
disfunction, it predicted the CLR for other drugs that are
substrates for OAT1,3 reasonably accurate, as compared to
popPK CLR predictions for these drugs. Assuming clearance
to be only mediated by GF and ATS, for piperacillin the
PBPK CLR predictions over an age-range of 2.5 months to 15
years lead to a %RMSPE of 21.8% [%PE: −33.2–25.4%] with
a trend towards over-prediction for children older than 1
year. For cefazolin, extrapolation of CLR predictions to near
term neonates with ages between 1- and 30-days lead to a
%RMSPE of 22.2% [%PE: −34.4%–46%.], with a trend
towards under-prediction for children older than 10 days.
Previously, Hayton et al. used para-aminohippurate to
derive an ontogeny profile of undifferentiated active renal
secretion in vivo, concluding that 50% maturation is achieved
around 1 year of age (3), which is comparable with our
findings. Recently, more insight into differentiated ontogeny
profiles of individual renal transporters have been quantified
based on direct measurements of the expression of
transporter-specific proteins in kidney samples taken post-
mortem from children of various ages, as described in detail
by Cheung et al. (9). This group characterized the ontogeny of
OAT1,3 as a sigmoidal function based on PNA in weeks with
children reaching half of the adult values around 8 months of
age (TM50 = 30.7 weeks [95% CI: 16.64–50.97]) and the
steepness of the ontogeny slope given by a hill coefficient of
0.51 (95% CI: 0.35–0.71). While our findings align with
Cheung et al. regarding the age at which half of the adult
level is reached, which was estimated to be around 7 months
with our function, we found a steeper ontogeny for OAT1,3,
as shown by a 2-fold higher estimated hill coefficient. The
impact of these differences on the ontogeny profiles is
illustrated in Fig. 4. This figure shows relatively similar
OAT1,3 ontogeny found by both methods at ages above the
TM50 values, but for younger ages the function quantified in
our work shows lower ontogeny values. Given the low
number of observed values at these younger ages in both
analyses, the uncertainty around the ontogeny below 7
months of age is high for both analyses. More data are
required to establish the accuracy of the estimated in vivo
functional ontogeny profile in the first year of life.
Although drugs may be predominantly eliminated by a
particular pathway, they are rarely exclusively cleared
through a single, well-defined pathway. However, despite
the fact that the estimated functional OAT1,3 ontogeny
profile may be impacted by minor elimination pathways
contributing to the clearance of clavulanic acid and amoxicil-
lin, this function could be used to obtain accurate pediatric
PBPK-based CLR predictions for two other drugs that are
predominantly, though not exclusively, eliminated through
GF and OAT1,3-mediated ATS, namely piperacillin and
cefazolin. Despite small trends towards over and under-
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prediction respectively, CLR predictions for piperacillin and
cefazolin were reasonably accurate with %RMSPE of 21.8
and 22.2%, which is well below the 2-fold error, which is the
generally accepted criterion for accuracy of PBPK predic-
tions. The tendency towards over-prediction of pediatric
PBPK CLR for piperacillin could be explained by other
processes involved in renal elimination that are not accounted
for in the PBPK model. It could for instance be that there is
passive or active reuptake of these drugs in the kidneys.
Alternatively, the authors of the popPK model that served as
the reference values, reported a (temporary) impairment of
the renal maturation function (29) which could explain the
lower CLR values obtained with the popPK model as
compared to the PBPK CLR predictions, the latter of which
does not take (potential) renal impairment into account. A
second drug, cefazolin, was used to assess the accuracy of this
function for extrapolations to term newborns below 1 month
of age. Remarkably, despite a small trend towards under-
prediction of CLR values for cefazolin in part of the
newborns, all predictions can still be considered accurate.
The methodology proposed here is the first to enable the
assessment of functional in vivo activity, rather than mRNA
Fig. 2. Contribution of clearance through glomerular filtration (CLGF – bottom blue boxes) and through
active tubular secretion (CLATS – top orange boxes) to total renal clearance of amoxicillin (CLR – sum of
blue and orange boxes) for each pediatric patient of the studied population sorted and grouped by age. The
numbers in each box show the relative contribution of CLGF and CLATS to total CLR for each individual
Fig. 3. Renal clearance (CLR) of piperacillin (a) and cefazolin (b) versus age in pediatric patients in children (a) and
neonates (b). The pediatric PBPK CLR predictions (dark blue) are overlaid with the typical CLR estimates obtained with the
published population pharmacokinetic model (orange)
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or transporter expression or ex vivo activity. As such it cannot
only augment the currently available methods to study renal
transporter maturation throughout the pediatric age-range,
but can also offer a valuable new dimension to this research.
Essential in our approach is the requirement of data on two
probe drugs that are predominantly excreted by specifically
GFR and a combination of GFR and ATS through a specific
transporter. As studies in healthy pediatric populations are
not allowed, the two probe drugs would have to be regularly
prescribed for therapeutic purposes in children across the
entire age-range. Furthermore, practical and ethical con-
straints may require assumptions to be made in the imple-
mentation of this method. For instance, in the example used
here to illustrate our approach, we assumed exclusive
elimination of our probe drugs through GF and OAT1,3-
mediated ATS, as ethical and practical constraints prevent
urine collection over prolonged durations and thereby the
formal assessment of the contribution of renal excretion to
overall drug elimination. This may have impacted the
accuracy of the obtained ontogeny function, but it does not
impact our proposed methodology conceptually. If informa-
tion on minor elimination routes would become available, this
could be included in the PBPK model to further refine the
estimated ontogeny function.
CONCLUSION
The ontogeny of functional in vivo OAT1,3 activity was
derived by using a combined population PK and PBPK
modeling approach. This popPBPK approach leverages the
knowledge on underlying physiological processes included in
PBPK models and information carried by individual PK
parameters as quantified with a population approach, to
derive parameters that cannot be measured in vivo. With this
methodology we derived the renal OAT1,3 transporter
ontogeny in vivo. This ontogeny function was included in
the pediatric PBPK-based model CLR for two other OAT1,3
substrates and on average predicted CLR throughout the
entire pediatric age-range accurately. This methodology could
be applied to other transporters substrates to characterize the
in vivo ontogeny of the remaining renal transporters to
further increase our understanding on renal development
and increase the accuracy in predicting pediatric CLR.
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